Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 22.2% | 23.5% | 12.1% | 22.7% | 26.9% | 28.5% | 20.4% | 20.1% | 23.2% | 9.9% | 9.7% | 7.4% | 6.5% | 1.8% | 7.7% | 11.9% | 14.0% | 20.5% | 19.0% | 15.1% |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is 14.4%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for Abbott Laboratories have been 17.6% over the past three years, and 16.6% over the past five years.
As of today, Abbott Laboratories's Return on Equity (ROE) is 14.4%, which is higher than industry median of (22.6%). It indicates that Abbott Laboratories's Return on Equity (ROE) is Good.